1. Academic Validation
  2. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist

Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist

  • Eur J Pharmacol. 2006 Dec 15;552(1-3):36-45. doi: 10.1016/j.ejphar.2006.08.063.
Julia N Heinrich 1 Julie Brennan Margaret H Lai Kelly Sullivan Geoff Hornby Mike Popiolek Li-Xin Jiang Mark H Pausch Gary Stack Karen L Marquis Terrance H Andree
Affiliations

Affiliation

  • 1 Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543-8000, USA. heinrij@wyeth.com
Abstract

The pharmacology of aplindore (DAB-452) was characterized in CHO-K1 cells stably transfected with the human dopamine D(2) receptor short isoform (CHO-D(2s)) and in a behavioral model for post-synaptic agonism in rats. In [(3)H]-spiperone competition binding studies, aplindore showed high affinity for dopamine D(2) and D(3) receptors and low affinity for the dopamine D(4), serotonin (5-HT)(1A), 5-HT(2) receptors and the alpha1-adrenoceptor. The high potency partial agonist activity of aplindore was demonstrated in [(35)S]guanosine 5'-O-(3-thiotriphosphate) ([(35)S]GTPgammaS) binding, extracellular signal-regulated kinase (ERK)-phosphorylation and intracellular calcium flux assay using fluorometric plate reader ([CA(2+)](i)-FLIPR) format. The [CA(2+)](i)-FLIPR assay was conducted with CHO-D(2S) receptor cells also stably expressing chimeric G(alphaq/o)-proteins. In all assay modalities, the potencies and intrinsic activities of aplindore were lower than dopamine and higher than aripiprazole. In contrast to the [(35)S]GTPgammaS binding and ERK-phosphorylation assays, the [CA(2+)](i)-FLIPR assay was able to detect the low partial agonist activity of SDZ 208-912. In unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats, aplindore induced contralateral turning, which was blocked by the dopamine D(2) receptor antagonist raclopride. The dopamine D(2) receptor selective partial agonist profile of aplindore suggests that it should be effective for the treatment of dopaminergic-based disorders, such as schizophrenia and Parkinson's disease.

Figures
Products